NICE ya found this figured but document doesn't say america but it sounds like american law to me, not sure about the symbol
MEDICINES CONTROL COUNCIL
SECTION 21 APPLICATION
COUNCIL'S RESPONSIBILITIES AND LIABILITY WHEN PERFORMING ITS FUNCTION IN TERMS OF SECTION 21 OF ACT 101 OF 1965
In terms of this Section the Authority/Council may authorize the sale of unregistered orthodox medicine, complementary medicine, and veterinary medicine or device for certain purposes.
21. (1) The authority may in writing authorize any person to sell during a specified period to any specified person or institution a specified quantity of orthodox medicine, complementary medicine, veterinary medicine or device, which is not registered.
21. (2) Any orthodox medicine, complementary medicine, veterinary medicine or device sold in pursuant to any authorization under sub-section (1) and in such a manner and during such period as the Authority may in writing determine.
21. (3) Authority may at any time by notice in writing withdraw the authorization granted in terms of sub-section (1) if effect is not given to any determination made in terms of sub-section (2)
An applicant who wishes to sell an unregistered medicine must be fully informed and be able to respond if his request is not successful.
Section 21 mandates the Authority to approve the use of unregistered medicine. The Authority, therefore, is required to address the following requirements of Section 21.
- Authorise sales
- Specify the period of sale
- Specify the purchaser or institution
- Specify the quantity of medicine
- Determine the purpose for the use of such medicine
- Determine the manner of use
- Determine the period of use
- Withdrawal of the authority to sell or use
--
1 Objective
The objective of Section 21 of this policy is to determine how an unregistered medicine can be authorized under Section 21.
2 Responsibility
The Authority shall delegate the administration of the control of the execution to the appropriate qualified person (Clinical Pharmacologist or Medicine Control Officer)
3 Source document
Section 21 of Act 101 of 1965
4 Policy
4.1 The Authority shall in writing authorize any person to sell during a specified period up to (six months) to any specified person or institution a specified quantity of any medicine, which is not registered.
4.2 All applicants must submit the following information:
(a) Name, street address and telephone number of the applicant/medical practitioner
(b) Registration number of the prescriber
(c) Name and address of the patient
(d) Diagnosis of the patient
(e) Dose, frequency and route of administration of the product
(f) Number and frequency of repeats
(g) Concomitant medication
(h) Name and (Generic) of the product
(i) Motivation why an unregistered product is to be used
(j) Reasons for not using similar registered product/current regimen
(k) Urgent applications can be handled by telephone in case of an emergency but the above mentioned information must be supplied before an authorization number is supplied.
A telephonic request must be followed up in writing within 48 hours.
Requests can only be repeated after a follow-up reports have been submitted to the supplier and the Authority.
In case of long term treatment a follow-up report must be submitted every six months. A new authorization number must be obtained every six months.
The officer designated must confirm the authorization in writing.
The patient must be fully informed that the drug is not registered with the authority.
The patient must be fully informed about the possible benefits and risks of the product.
The patient must sign the informed consent. In case of a minor the parent or guardian must sign the informed consent.
If approved, the product shall only be used for the treatment of the patient in such a manner and for the approved period only. No other patient may receive the authorized unregistered medicine.
All adverse events or unexpected events must be reported to the Authority.
At the termination of treatment a full case report shall be submitted to the Authority.
The Authority shall in writing withdraw any such authorization.
All unused unregistered products shall be returned to the supplier for disposal according to the requirements of the Authority.
Information about the basic efficacy, safety and quality about the product must be supplied to the authority.
Where the product is used for the clinical trial, the MBR1 form must include the formula of the final product in terms of a dosage unit:
a) Specifications of the final product namely
viz the name of the specification, limits of criteria of acceptance of all physical, chemical and where applicable microbial parameters.
b) The laboratory responsible for the final lot release locally. At least an identification and assay must be done if the product is imported.
c) Stability data derived from the product stored at room temperature (at least nine months), and elevated conditions (three months) in tabulated form. The date of manufacture, batch number, batch size and container must be stated.
The Registrar, when the Authority is not sitting, refer as far as possible all matters and report thereon to the next meeting of Council.
An exemption will be given for investigational and comparator medicines which:
a) are new chemical entities
b) are new or different dose forms, delivery systems and formulations of established medicines, which
c) does not have consent to be sold in the Republic of South Africa
The Authority may grant the approval after receiving approval from an accredited ethics committee for the study protocol and the justification and validity of the study protocol.